Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
3.730
-0.060 (-1.58%)
At close: Oct 7, 2026, 4:00 PM EDT
3.880
+0.150 (4.02%)
Pre-market: Oct 8, 2026, 7:00 AM EDT
Bicycle Therapeutics Employees
Bicycle Therapeutics had 288 employees as of December 31, 2025. The number of employees decreased by 17 or -5.57% compared to the previous year. That makes Bicycle Therapeutics the 24,143rd largest employer in the world and 3,118th in the United States.
Employees
288
Change (1Y)
-17
Growth (1Y)
-5.57%
Revenue / Employee
$212,517
Profits / Employee
-$661,153
Market Cap
261.07M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 288 | -17 | -5.57% |
| Dec 31, 2024 | 305 | 21 | 7.39% |
| Dec 31, 2023 | 284 | 48 | 20.34% |
| Dec 31, 2022 | 236 | 117 | 98.32% |
| Dec 31, 2021 | 119 | 32 | 36.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| EyePoint | 214 |
| Rocket Pharmaceuticals | 202 |
| Fate Therapeutics | 161 |
| BridgeBio Oncology Therapeutics | 88 |
| SAB Biotherapeutics | 86 |
| Lexeo Therapeutics | 63 |
BCYC News
- 15 days ago - Bicycle Therapeutics treatment of pancreatic cancer granted orphan designation - TheFly
- 2 months ago - Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatch - PYMNTS
- 2 months ago - Bicycle Therapeutics assumed with an Outperform at Oppenheimer - TheFly
- 2 months ago - Bicycle Therapeutics reports Q2 EPS (72c), consensus (58c) - TheFly
- 2 months ago - Bicycle Therapeutics sees cash runway into 2030 - TheFly
- 2 months ago - Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Business Wire
- 2 months ago - Bicycle Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Bicycle Therapeutics Earnings release: Q2 2026 - Filings